Compare BIO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | ROIV |
|---|---|---|
| Founded | 1952 | 2014 |
| Country | United States | United Kingdom |
| Employees | 7450 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 20.7B |
| IPO Year | N/A | 2021 |
| Metric | BIO | ROIV |
|---|---|---|
| Price | $281.97 | $28.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $339.75 | $27.56 |
| AVG Volume (30 Days) | 269.3K | ★ 4.2M |
| Earning Date | 04-30-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $3.21 | $878.32 |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $211.43 | $9.24 |
| 52 Week High | $343.12 | $30.33 |
| Indicator | BIO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 54.67 |
| Support Level | $256.85 | $26.45 |
| Resistance Level | $289.61 | $30.33 |
| Average True Range (ATR) | 7.95 | 0.95 |
| MACD | 2.05 | -0.03 |
| Stochastic Oscillator | 75.33 | 79.03 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.